Bristol-Myers’s Drug Combination Boosts Lung Cancer Benefit
- Opdivo plus Yervoy shrinks tumors in 39% to 47% of patients
- Twelve of 13 patients with PD-L1 biomarker responded to drugs
This article is for subscribers only.
The combination of two Bristol-Myers Squibb Co. drugs that markedly improved the treatment of melanoma appears to have the same benefit for patients with the most common and often deadly form of lung cancer.
Patients getting a mixture of Opdivo and Yervoy had a 39 percent response rate, meaning their tumors shrank after treatment, while the combination using Yervoy less often did better, with 47 percent of patients improving. A separate group getting Opdivo alone had a 23 percent response, though the trial wasn’t designed to directly compare the groups.